Asset Allocation

As of March 31, 2026.
Type % Net
Cash 0.32%
Stock 63.23%
Bond 35.54%
Convertible 0.00%
Preferred 0.00%
Other 0.90%
View Asset Allocation
Start Trial

Market Capitalization

As of March 31, 2026
Large 62.76%
Mid 24.86%
Small 12.38%
View Market Capitalization
Start Trial

Region Exposure

% Developed Markets: 96.91%    % Emerging Markets: 1.00%    % Unidentified Markets: 2.09%

Americas 89.85%
89.84%
Canada 0.08%
United States 89.75%
0.02%
Mexico 0.01%
As of March 31, 2026. Region breakdown data is calculated by using the long position holdings of the portfolio.
Greater Europe 7.81%
United Kingdom 2.35%
5.23%
France 0.29%
Ireland 1.78%
Netherlands 1.11%
Spain 0.99%
Switzerland 0.57%
0.00%
0.23%
Israel 0.11%
Saudi Arabia 0.12%
Greater Asia 0.25%
Japan 0.00%
0.17%
Australia 0.17%
0.08%
South Korea 0.08%
0.00%
Unidentified Region 2.09%

Bond Credit Quality Exposure

AAA 4.40%
AA 65.18%
A 12.86%
BBB 15.07%
BB 0.00%
B 0.00%
Below B 0.00%
    CCC 0.00%
    CC 0.00%
    C 0.00%
    DDD 0.00%
    DD 0.00%
    D 0.00%
Not Rated 0.00%
Not Available 2.49%
Short Term 0.00%
As of March 31, 2026
View Bond Credit Quality Exposure
Start Trial

Stock Sector Exposure

Cyclical
24.71%
Materials
0.00%
Consumer Discretionary
5.21%
Financials
17.45%
Real Estate
2.06%
Sensitive
58.59%
Communication Services
7.94%
Energy
4.47%
Industrials
10.23%
Information Technology
35.96%
Defensive
16.70%
Consumer Staples
2.48%
Health Care
12.75%
Utilities
1.47%
Not Classified
0.00%
Non Classified Equity
0.00%
Not Classified - Non Equity
0.00%
As of March 31, 2026
View Region Exposure
Start Trial

Bond Sector Exposure

As of March 31, 2026
Type % Net
Government 63.21%
Corporate 28.48%
Securitized 6.64%
Municipal 1.68%
Other 0.00%
View Bond Sector Exposure
Start Trial

Bond Maturity Exposure

Short Term
0.35%
Less than 1 Year
0.35%
Intermediate
68.12%
1 to 3 Years
20.49%
3 to 5 Years
30.03%
5 to 10 Years
17.60%
Long Term
31.31%
10 to 20 Years
16.22%
20 to 30 Years
11.83%
Over 30 Years
3.26%
Other
0.23%
As of March 31, 2026
View Bond Maturity Exposure
Start Trial